Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression

Major depressive disorder (MDD) is a prevalent debilitating psychiatric mood that contributes to increased rates of disability and suicide. However, the pathophysiology underlying MDD remains poorly understood. A growing number of studies have associated dysfunction of the prefrontal cortex (PFC) with depression, but no proteomic study has been conducted to assess PFC protein expression in a preclinical model of depression. Using the chronic unpredictable mild stress (CUMS) rat model of depression, differential protein expression between the PFC proteomes of CUMS and control rats was assessed through two-dimensional electrophoresis followed by matrix-assisted laser desorption ionization-time of flight-tandem mass spectrometry. Differential protein expression was analyzed for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway over-representation. Four differential proteins were selected for Western blotting validation. Twenty-nine differential proteins were identified in the PFC of CUMS rats relative to control rats. Through KEGG analysis, energy and glutathione metabolic pathways were determined to be the most significantly altered biological pathways. Two of the four differential proteins selected for Western blotting validation - glyoxalase 1 and dihydropyrimidinase-related protein 2 - were found to be significantly downregulated in CUMS relative to control rats. In conclusion, proteomic analysis reveals that energy and glutathione metabolism are the most significantly altered biological pathways in the CUMS rat model of depression. Further investigation on these processes and proteins in the PFC is key to a better understanding of the underlying pathophysiology of MDD.

[1]  G. Rajkowska,et al.  Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. , 2010, The international journal of neuropsychopharmacology.

[2]  C. Stockmeier,et al.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[4]  Fa-jin Lv,et al.  Neurogenesis and major depression: implications from proteomic analyses of hippocampal proteins in a rat depression model , 2007, Neuroscience Letters.

[5]  P. Xie,et al.  Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. , 2012, The international journal of neuropsychopharmacology.

[6]  R. Hashimoto,et al.  A two-stage case–control association study of the dihydropyrimidinase-like 2 gene (DPYSL2) with schizophrenia in Japanese subjects , 2010, Journal of Human Genetics.

[7]  Tzu-Hao Wang,et al.  Differential proteomics analysis of amniotic fluid in pregnancies of increased nuchal translucency with normal karyotype , 2011, Prenatal diagnosis.

[8]  M. Mann,et al.  Comparative Proteomic Phenotyping of Cell Lines and Primary Cells to Assess Preservation of Cell Type-specific Functions , 2009, Molecular & Cellular Proteomics.

[9]  Han Liu,et al.  Hippocampal synaptic dysregulation of exo/endocytosis-associated proteins induced in a chronic mild-stressed rat model , 2013, Neuroscience.

[10]  E. Domenici,et al.  Regulation of cytoskeleton machinery, neurogenesis and energy metabolism pathways in a rat gene-environment model of depression revealed by proteomic analysis , 2011, Neuroscience.

[11]  J. Mazziotta,et al.  Reduction of prefrontal cortex glucose metabolism common to three types of depression. , 1989, Archives of general psychiatry.

[12]  Jun-Feng Wang,et al.  Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. , 2011, The international journal of neuropsychopharmacology.

[13]  M. Webster,et al.  Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients , 2012, Translational Psychiatry.

[14]  Patricia A. Berglund,et al.  The Epidemiology of Major Depressive Disorder , 2009 .

[15]  Margaret G. Distler,et al.  Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights , 2012, Front. Gene..

[16]  Jun-Feng Wang,et al.  Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. , 2011, The international journal of neuropsychopharmacology.

[17]  Matthew L. Ho,et al.  Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. , 2003, The American journal of psychiatry.

[18]  P. Xie,et al.  Increased apoptosis and different regulation of pro-apoptosis protein bax and anti-apoptosis protein bcl-2 in the olfactory bulb of a rat model of depression , 2011, Neuroscience Letters.

[19]  Oxidative Parameters in the Rat Brain of Chronic Mild Stress Model for Depression: Relation to Anhedonia-Like Responses , 2012, The Journal of Membrane Biology.

[20]  A. Subramanian,et al.  Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. , 2000, The Journal of biological chemistry.

[21]  C. Ebner,et al.  Clinical effects of electroconvulsive therapy in severe depression and concomitant changes in cerebral glucose metabolism--an exploratory study. , 2013, Journal of affective disorders.

[22]  N. Anderson,et al.  Proteome and proteomics: New technologies, new concepts, and new words , 1998, Electrophoresis.

[23]  P. Guest,et al.  Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function , 2012, European Archives of Psychiatry and Clinical Neuroscience.

[24]  M. Molloy,et al.  Membrane proteins and proteomics: Un amour impossible? , 2000, Electrophoresis.

[25]  J. Thome,et al.  Proteomic research in psychiatry , 2011, Journal of psychopharmacology.

[26]  Yoshifumi Watanabe,et al.  Reduced expression of glyoxalase-1 mRNA in mood disorder patients , 2008, Neuroscience Letters.

[27]  R. Post,et al.  Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. , 1996, Psychopharmacology bulletin.

[28]  P. Slonimski,et al.  Réseau d'interactions entre des gènes non liés: régulation synergique ou antagoniste de la synthèse de l'iso-l-cytochrome c, de l'iso-2-cytochrome c et du cytochrome b2 , 1976 .

[29]  J. Coorssen,et al.  Quantitative proteomics: assessing the spectrum of in-gel protein detection methods , 2011, Journal of chemical biology.

[30]  R. Yolken,et al.  Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder , 2000, Molecular Psychiatry.

[31]  Yan Liu,et al.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.

[32]  Deanna M Barch,et al.  Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. , 2009, Journal of affective disorders.

[33]  D. Schutter.  Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis , 2008, Psychological Medicine.

[34]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[35]  M. Ehlers,et al.  Microanatomy of dendritic spines: emerging principles of synaptic pathology in psychiatric and neurological disease , 2004, Biological Psychiatry.

[36]  P. Willner.  Chronic Mild Stress (CMS) Revisited: Consistency and Behavioural-Neurobiological Concordance in the Effects of CMS , 2005, Neuropsychobiology.

[37]  Jordan Grafman,et al.  The functional neuroanatomy of depression: Distinct roles for ventromedial and dorsolateral prefrontal cortex , 2009, Behavioural Brain Research.

[38]  B. H. Miller,et al.  Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains , 2011, Psychopharmacology.

[39]  Daniel Martins-de-Souza,et al.  The role of proteomics in depression research , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[40]  D. Bakish,et al.  New standard of depression treatment: remission and full recovery. , 2001, The Journal of clinical psychiatry.

[41]  Peter Herscovitch,et al.  Regional cerebral glucose utilization in patients with a range of severities of unipolar depression , 2002, Biological Psychiatry.